Galena Biopharma and Dr. Reddy's Laboratories Ltd. announced a strategic development and commercialization partnership on NeuVax(TM) (nelipepimut-S) in India. NeuVax(TM) (nelipepimut-S) is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes following binding to HLA-A2/A3 molecules on antigen presenting cells.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6,640 INR | -0.04% | +0.65% | +14.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.51% | 13.24B | |
+55.35% | 815B | |
+31.64% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+15.51% | 247B | |
+16.72% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- DRREDDY Stock
- News Dr. Reddy's Laboratories Limited
- Galena Biopharma and Dr. Reddy's Laboratories Ltd. Announce Strategic Partnership for NeuVax(TM) in India